Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 668-675

  Graziano, Stephen L ^a   Gamble, Gary P ^a   Newman, Nancy B ^a   Abbott, Lynn Z ^a   Rooney, Michelle ^a   Mookherjee, Sulagna ^a   Lamb, Melissa L ^a   Kohman, Leslie J ^a   Poiesz, Bernard J ^a  

^a SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CODON; FEMALE; GENE MUTATION; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA;

EID: 0032975370     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.668     Document Type: Article

References (43)

1. Graziano SL: Non-small cell lung cancer: Clinical value of new biological predictors. Lung Cancer 17:S37-S58, 1997 (suppl 1)
2. Gail MH, Eagan RT, Feld R, et al: Prognostic factors in patients with resected stage I non-small cell lung cancer: A report from the Lung Cancer Study Group. Cancer 54:1802-1813, 1984
3. Takise A, Kodama T, Shimosato Y, et al: Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 61:2083-2088, 1988
4. Isobe H, Miyamoto H, Shimizu T, et al: Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 65:1391-1395, 1990
5. Zimmerman PV, Bint MH, Hawson GAT, et al: Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2:530-533, 1987
6. Slebos RJC, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
7. Harada M, Dosaka-Akita H, Miyamoto H, et al: Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69:72-77, 1992
8. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5187, 1990
9. Lee JS, Ro JY, Sahin AA, et al: Expression of blood-group antigen A: A favorable prognostic factor in non-small cell lung cancer. N Engl J Med 324:1084-1090, 1991
10. Horio Y, Takahashi T, Kuroishi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1-4, 1993
11. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 89:881-886, 1997
12. Richardson GE, Johnson BE: The biology of lung cancer. Semin Oncol 20:105-127, 1993
13. Rodenhuis S, van de Wetering MLM, Mooi WJ, et al: Mutational activation of the K-ras oncogene: A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929-935, 1987
14. Mitsudomi T, Viallet J, Mulshine JL, et al: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353-1362, 1991
15. Sugio K, Ishida T, Yokoyama H, et al: ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903-2906, 1992
16. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
17. Rodenhuis S, Slebos RJC, Boot AJM, et al: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48:5738-5741, 1988
18. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986 (suppl)
19. Mountain CF: Revisions in the International System for staging lung cancer. Chest 111:1710-1717, 1997
20. Shimizu K, Birnbaum D, Ruley MA, et al: Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. Nature 304:497-500, 1983
21. Santos E, Martin-Zanca D, Reddy EP, et al: Malignant transformation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223:661-664, 1984
22. Anderson MA, Gusella JF: Use of cyclosporin A in establishing Epstein-Barr virus transformed human lymphoblastoid cell lines. In Vitro 20:856-858, 1984
23. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1987
24. Iannone R, Sherman MP, Rodgers-Johnson PEB, et al: HTLV-I DNA sequences in CNS tissue of a patient with tropical spastic paraparesis and HTLV-I associated myelopathy. J Acquir Immune Defic Syndr 5:810-816, 1992
25. Sharkey DJ, Scalice ER, Christy KG Jr, et al: Antibodies as thermolabile switches: High temperature triggering for the polymerase chain reaction. Bio/Technology 12:506-509, 1994
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Kalbfleisch JD, Prentice RT: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
28. Procedure for proportional hazard regression. Version 6.09. Cary, NC, SAS Institute, Inc, 1988
29. Cox DR, Oakes D: Analysis of Survival Data. London, United Kingdom, Chapman and Hall, 1984
30. Bishop YM, Fienberg SE, Holland PW: Discrete Multivariate Analysis: Theory and Practice. Cambridge, MA, MIT Press, 1975
31. Mitsudomi T, Steinberg SM, Oie HK, et al: ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999-5002, 1991
32. Kern JA, Slebos RJC, Top B, et al: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516-520, 1994
33. Silini EM, Bosi F, Pellegata NS, et al: K-ras gene mutations: An unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch 424:367-373, 1994
34. Isobe T, Hiyama K, Yoshida Y, et al: Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 85:1240-1246, 1994
35. Rosell R, Li S, Skacel Z, et al: Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8:2407-2412, 1993
36. Rosell R, Monzo M, Pifarre A, et al: Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 2:1083-1086, 1996
37. Keohavong P, DeMichele MAA, Melacrinos AC, et al: Detection of K-ras mutations in lung carcinomas: Relationship to prognosis. Clin Cancer Res 2:411-418, 1996
38. Cho JY, Kim JH, Lee YH, et al: Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 79:462-467, 1997
39. Siegfried JM, Gillespie AT, Mera R, et al: Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 6:841-847, 1997
40. Nemunaitis J, Klemow S, Tong A, et al: Prognostic value of K-ras mutations, ras oncoprotein, and c-erbB-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 21:155-160, 1998
41. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 16:2468-2477, 1998
42. Rodenhuis S, Slebos RJC: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665S-2669S, 1992 (suppl)
43. Finkelstein SD, Sayegh R, Bakker A, et al: Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128:526-532, 1993